Bart Barlogie

High Impact

Distinguished Professor of Medicine and Pathology

UAMS primary UA Little Rock University of Arkansas

Also affiliated: Northwestern University (2005); University of North Carolina at Chapel Hill (2005); Creighton University (2007–2009); Louisiana State University (2002); University of Maryland, Baltimore (2002–2003); Cedars-Sinai Medical Center (2002–2010); Brigham and Women's Hospital (2006); Roswell Park Comprehensive Cancer Center (2010); National Institutes of Health (1992–1997); Arkansas Children's Hospital (1998); St Bartholomew's Hospital (2003); Sparrow Health System (2009); Cleveland Clinic (2004); Mount Sinai Hospital (2016–2021); Hackensack University Medical Center (2003–2006); Mayo Clinic (2001–2010); Carolinas Healthcare System (2015); Memorial Sloan Kettering Cancer Center (2003–2010); The University of Texas MD Anderson Cancer Center (1976–2009); Harvard University (2003–2008); University of Arizona (1997); Emory University (2005); University of Alberta (2004); Inserm (2003); Eastern Virginia Medical School (1996); Lebanese University (2004); University of California, Los Angeles (2002); The University of Texas System (1976–2009); The University of Texas at San Antonio Health Science Center (2001); Duke University (2009); Universidad de Salamanca (2005–2010); Wayne State University (2009); National and Kapodistrian University of Athens (2010–2015); Medical College of Wisconsin (1999–2003); Max Delbrück Center (2006); Cornell University (2001–2010); Heidelberg University (2015); University of Münster (1972–2008); University of Pavia (2003); Louisiana State University in Shreveport (2002); University of Michigan (2009); University Hospitals of Cleveland (2006); University of Arkansas Medical Center (1991–2025); Sparrow Hospital (2009); University Hospital Heidelberg (2015); Henry Ford Hospital (2001–2006); Karolinska Institutet (2003); Centre Hospitalier Universitaire de Lille (2023); Centre Hospitalier Universitaire de Nantes (2010); Moffitt Cancer Center (2009); Christian-Albrechts-Universität zu Kiel (1994); Yale University (2009); University of Chicago (2004); Universitätsklinikum Erlangen (2003); Northwestern Memorial Hospital (2005); Fred Hutch Cancer Center (1997–2023); The Barbara Ann Karmanos Cancer Institute (2006–2009); Saint Vincent's Catholic Medical Center (2005–2010); Wilhelminen Hospital (2010); Central Arkansas Veterans Healthcare System (2001–2002); Levine Cancer Institute (2017); Cancer Research And Biostatistics (2003–2015); University Hospital Münster (1972–1985); Hospital Clínic de Barcelona (2005–2010); Dana-Farber Cancer Institute (2003–2009); Myeloma UK (2007); Mayo Clinic in Arizona (2005–2010); Duke Medical Center (2009); Harrington Cancer Center (2002); Frederick National Laboratory for Cancer Research (1997); Dana-Farber/Harvard Cancer Center (2003); The Institute of Statistical Mathematics (2012); National Cancer Institute (1992–2012); Children's Hospital of The King's Daughters (1996); Hôpital Saint-Louis (2010); Hospital Posadas (2004); Erasmus MC Cancer Institute (2019); The US Oncology Network (2009); Institute for Myeloma & Bone Cancer Research (2005–2006); John L. McClellan Memorial Veterans Hospital (1997); Hôpital Claude Huriez (2023); Loyola Medicine (1999); Fachklinik Hornheide (2008); Dana-Farber Brigham Cancer Center (2006); Columbus Community Clinical Oncology Program (2002); SWOG Cancer Research Network (2001–2005); Weill Cornell Medicine (2010); University of Arizona Cancer Center (1997–2002); Robert H. Lurie Comprehensive Cancer Center of Northwestern University (2006); UCLA Jonsson Comprehensive Cancer Center (2002); Winship Cancer Institute (2005); University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center (2003); Tisch Cancer Institute (2016–2022); Cross Cancer Institute (2004); Daniel den Hoed Kliniek (1984); Takeda Oncology (United States) (2005–2006); AbbVie Biotherapeutics (United States) (2009); Wake Forest University (2006); Fraunhofer-Gesellschaft (2008); University of Oklahoma Health Sciences Center (2005–2010); University of Turin (2015); University of Tennessee at Knoxville (2004); Columbia University (2015); University of Pennsylvania (2010); Rockefeller University (2001–2009); University of California, Davis (2001); Texas Tech University Health Sciences Center (2002); University of Bologna (2006–2015); Icahn School of Medicine at Mount Sinai (2015–2022)

139 h-index 1142 pubs 77,164 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website Research Group

OverviewAI-generated summary

Bart Barlogie's research focuses on multiple myeloma, a cancer of plasma cells. His work has contributed to the development and refinement of staging systems and response criteria for this disease, including the International Staging System for Multiple Myeloma (2005) and International Uniform Response Criteria for Multiple Myeloma (2006). He has investigated the antitumor activity of various therapeutic agents, such as thalidomide in refractory multiple myeloma (1999) and bortezomib in relapsed, refractory myeloma (2003).

Barlogie's research also delves into the underlying molecular mechanisms of multiple myeloma. This includes studying the role of specific signaling pathways, such as the Wnt-signaling pathway and its antagonist DKK1 in the development of osteolytic lesions (2003), and the engagement of NF-κB pathways in the disease (2007). His group has also worked on molecular classification and gene expression profiling to identify high-risk forms of multiple myeloma (2006).

With a significant publication record, including over 1145 publications and an h-index of 139, Barlogie is recognized as a highly cited researcher. He collaborates with several colleagues at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, Maurizio Zangari, Sharmilan Thanendrarajan, and John D. Shaughnessy, with whom he has co-authored multiple publications.

Metrics

h-index: 139
Publications: 1142
Citations: 77,164

Positions

Distinguished Professor of Medicine and Pathology publications 1989–2025

University of Arkansas for Medical Sciences Institution web page

Selected Publications

Altered mesenchymal and endothelial subsets in interstitial bone marrow and focal lesions in myeloma patients and SCID-hu mice (2025)

Haematologica DOI OpenAlex
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025)

4 citations DOI OpenAlex
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024)

5 citations DOI OpenAlex
Second primary malignancies after tandem autologous hematopoietic stem cell transplantation for multiple myeloma (2024)

2 citations DOI OpenAlex
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024)

17 citations DOI OpenAlex
Three years of maintenance with VRD in multiple myeloma: results of total therapy IIIB with a 15-year follow-up (2023)

8 citations DOI OpenAlex
Impact of Dexamethasone (Dex) Dose Strength on Outcomes in Newly Diagnosed Multiple Myeloma (NDMM): A Secondary Analysis of SWOG Studies S0777 and S1211 (2023)

2 citations DOI OpenAlex
Sequential Imaging with Diffusion-Weighted Whole-Body MRI (DW-MRI) and PET-CT Identifies Patients at High Risk of Relapse in Multiple Myeloma (2023)

3 citations DOI OpenAlex
Resolving the spatial architecture of myeloma and its microenvironment at the single-cell level (2023)

30 citations DOI OpenAlex
A gene signature can predict risk of MGUS progressing to multiple myeloma (2023)

13 citations DOI OpenAlex
Curability of multiple myeloma (MM) based on relative survival rate (RSR) in patients (pts) treated on earlier total therapy (TT) protocols. (2023)

1 citation DOI OpenAlex
A Gene Signature Can Predict Risk of MGUS Progressing to Multiple Myeloma (2023)

SSRN Electronic Journal DOI OpenAlex
The spatio-temporal evolution of multiple myeloma from baseline to relapse-refractory states (2022)

65 citations DOI OpenAlex
CST6 suppresses osteolytic bone disease in multiple myeloma by blocking osteoclast differentiation (2022)

23 citations DOI OpenAlex
Feasibility of Outpatient Stem Cell Transplantation in Multiple Myeloma and Risk Factors Predictive of Hospital Admission (2022)

13 citations DOI OpenAlex